Corporate Overview

22nd Century Group, Inc. is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants through genetic engineering, gene-editing, and modern plant breeding. Our primary mission in tobacco is to greatly reduce the harm caused by smoking by bringing our reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets.

Why Invest

Icon

Redefining the cigarette category through science-based nicotine reduction

Icon

VLN® cigarettes are the world’s first and only FDA-authorized MRTP combustible cigarettes

Icon

A focused, margin-driven path to profitability

Stock Snapshot

Loading…

Company Reports

View All SEC Filings

Press Releases

View Press Release

Latest Presentation

 Investor Presentation - August 2025

Investor Presentation
January 2026

Download

Upcoming & Recent Events

XXII 2025 Third Quarter Results Call

XXII 2025 Third Quarter Results Call
Tuesday, November 4, 2025 · 8:00 AM ET

Join Webcast

View Notice

Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
View Notice
STIPULATION AND AGREEMENT OF SETTLEMENT
View Notice
Company

22nd Century Group, Inc.

321 Farmington Road

Mocksville, NC 27028

Investor Relations

Matt Kreps

22nd Century Group

Investor Relations

Phone: 214-597-8200

Email: mkreps@xxiicentury.com

Transfer Agent

Continental Stock & Transfer Company

1 State Street, 30th Floor

New York, NY 10004

Phone: 212-509-4000

Email: cstmail@continentalstock.com